journal
MENU ▼
Read by QxMD icon Read
search

Memo

journal
https://www.readbyqxmd.com/read/30220932/current-and-evolving-treatment-strategies-in-adult-immune-thrombocytopenia
#1
REVIEW
Jan-Paul Bohn, Michael Steurer
Immune thrombocytopenia (ITP) is an acquired autoimmune phenomenon resulting in low platelet count and increased bleeding risk. Goals of upfront management include prompt control of severe bleeding-which is rare-as well as induction and maintenance of a hemostatic platelet count. Thus, optimal management of ITP patients is often challenging and requires a highly individualized approach. Many patients may not suffer significant bleeding despite severe thrombocytopenia and the risk of toxicity associated with treatment may outweigh its benefit...
2018: Memo
https://www.readbyqxmd.com/read/30220931/thrombotic-thrombocytopenic-purpura
#2
REVIEW
Paul Knöbl
Thrombotic thrombocytopenic purpura (TTP) is a clearly defined entity of the thrombotic microangiopathies (TMA), a heterogeneous group of disorders characterized by microangiopathic hemolytic anemia with red cell fragmentation, thrombocytopenia and organ dysfunction due to disturbed microcirculation. TTP is characterized by a severe deficiency of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), an enzyme responsible for physiological cleavage of von Willebrand factor (VWF)...
2018: Memo
https://www.readbyqxmd.com/read/30220930/sabcs-2017-pathology-from-bench-to-bedside
#3
REVIEW
Zsuzsanna Bago-Horvath
The 40th International San Antonio Breast Cancer Symposium offered a multifaceted platform for the presentation of several innovative therapeutic approaches. The results of these preclinical and clinical studies provided insight into the development of novel therapy concepts from the laboratory bench to the bedside of breast cancer patients. One main focus of last year's symposium was the search for synergisms and opportunities for collaboration between basic research scientists and investigators in drug development...
2018: Memo
https://www.readbyqxmd.com/read/30220929/post-sabcs-local-therapy-and-radiology
#4
REVIEW
Florian Fitzal
This year there were three interesting oral presentations and several posters presenting important new data regarding local therapy (surgery and radiotherapy) as well as radiological aspects. This minireview is a personal view of the clinically most relevant data in this respect with the following conclusions: A micrometastasis is no indication for axillary dissection. The number of involved sentinel lymph nodes predicts non-sentinel lymph node metastasis and should be taken into account regarding omitting axillary dissection...
2018: Memo
https://www.readbyqxmd.com/read/30220928/sabcs-2017-lifestyle-factors-hormone-receptor-positive-advanced-disease-liquid-biopsies-and-prognosis
#5
REVIEW
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil
This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis. In a retrospective analysis of the Women's Health Initiative Observational Study, a reduction in the body mass index (BMI) of at least 5% within 3 years significantly reduced the risk of breast cancer compared to women with a stable weight (HR 0.77; 95% CI 0.78-0.98). In the MONALEESA-7 trial investigating ribociclib or placebo in combination with endocrine therapy as first-line treatment in pre- and perimenopausal women with hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer, a significantly longer progression-free survival was shown for patients treated with ribociclib compared to the placebo group (23...
2018: Memo
https://www.readbyqxmd.com/read/30220927/sabcs-2017-update-on-chemotherapy-targeted-therapy-and-immunotherapy
#6
REVIEW
Rupert Bartsch, Elisabeth Bergen
In the areas of chemotherapy, targeted therapy and immunotherapy, several interesting and clinically relevant data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). This short review focuses on dose-dense and/or sequential administration of adjuvant chemotherapy, provides an update on targeted therapies for HER2-positive and triple-negative breast cancer and summarizes new results in the field of immunotherapy.
2018: Memo
https://www.readbyqxmd.com/read/30220926/current-concepts-and-future-directions-in-neoadjuvant-chemotherapy-of-breast-cancer
#7
REVIEW
Rupert Bartsch, Elisabeth Bergen, Arik Galid
Preoperative administration of chemotherapy is a widespread treatment approach in early stage breast cancer whenever chemotherapy is indicated in principle. In addition, neoadjuvant treatment is today regarded as the preferred way of delivering systemic therapy in triple-negative and HER2-positive breast cancer. While preoperative chemotherapy allows for disease downstaging and increases breast conservation rates, achieving pathologic complete remission (pCR) is usually regarded as the most pertinent aim as pCR predicts for improved long-term outcome in high-risk breast cancer subtypes...
2018: Memo
https://www.readbyqxmd.com/read/30220925/demystification-of-palliative-care-what-palliative-care-teams-don-t-want-you-to-think-about-them
#8
Eva K Masel, Gudrun Kreye
There is robust data that palliative care is prolonging life while there are still prejudices towards this discipline that have to be demystified. Patients, relatives and caregivers benefit from the concept of early integration of palliative care and therefore, palliative care should not be mainly regarded as end-of-life care.
2018: Memo
https://www.readbyqxmd.com/read/30220924/long-term-remission-in-advanced-stage-hepatocellular-carcinoma-a-chance-for-cure
#9
REVIEW
Matthias Pinter, Wolfgang Sieghart
Liver resection, transplantation, and local ablation are potential curative treatment options but can only be offered to patients with early stage hepatocellular carcinoma (HCC). Patients with macrovascular tumor invasion and extrahepatic metastases are candidates for palliative systemic therapies. Achieving radiological complete response can be associated with long-term remission and excellent outcome. However, despite recent advancements in the medical treatment of advanced stage HCC, complete remission with available systemic treatment options still remains a rare event...
2018: Memo
https://www.readbyqxmd.com/read/30220923/cure-in-metastatic-breast-cancer
#10
REVIEW
Theresa Westphal, Simon Peter Gampenrieder, Gabriel Rinnerthaler, Richard Greil
Oligometastatic disease characterizes a distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several case series; however, unlike other tumor entities, prospective data are lacking. Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival...
2018: Memo
https://www.readbyqxmd.com/read/29983830/apply-a-prospective-observational-study-of-clinical-practice-patterns-of-darbepoetin-alfa-use-in-patients-with-chemotherapy-induced-anemia-in-romania
#11
Nicoleta Mariana Berbec, Dana Lucia Stanculeanu, Nicoleta Sorina Badelita, Mariana Vasilica, Dorel Ionel Popovici, Andrei Colita, Cristina Neacsu, Alexandru Iordan
Purpose: The primary objective of this study was to evaluate the compliance of Romanian physicians with the national therapeutic protocol and international guidelines on treatment with erythropoiesis-stimulating agents in anemic cancer patients receiving chemotherapy. The secondary objective was to assess the hemoglobin (Hb) level change due to anemia treatment and safety of darbepoetin alfa. Methods: This was a single-arm, prospective, longitudinal, multicenter, observational study in patients with nonmyeloid malignancies and symptomatic chemotherapy-induced anemia treated concomitantly with darbepoetin alfa...
2018: Memo
https://www.readbyqxmd.com/read/29983829/pitfalls-in-the-radiological-response-assessment-of-immunotherapy
#12
REVIEW
Lucian Beer, Maximilian Hochmair, Helmut Prosch
Immunotherapies comprise of a class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, with indications for melanoma, non-small lung cancer, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, and Hodgkin's lymphoma. Immune checkpoint inhibitors have demonstrated unique response patterns that are not adequately captured by traditional response criteria such das the Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization criteria...
2018: Memo
https://www.readbyqxmd.com/read/29983828/management-of-adverse-events-related-to-checkpoint-inhibition-therapy
#13
REVIEW
Jakob Daniel Rudzki
IO treatments (immuno-oncology treatments) have become reality and are now daily practice or, in some cases, a daily challenge. New recommendations are being made with the prime purpose of increasing alertness and awareness as well as emphasizing standard operating strategies to deal with immune-related adverse events (ir-AEs) in patients treated with immune checkpoint inhibitors (ICI). This brief review refers to systemic reviews, guidelines and meta-analyses, randomized controlled trials and case series published from 2000 to the present...
2018: Memo
https://www.readbyqxmd.com/read/29983827/chimeric-antigen-receptor-t%C3%A2-cell-therapy-a-hematological-success-story
#14
REVIEW
Philipp Wohlfarth, Nina Worel, Georg Hopfinger
Chimeric antigen receptor (CAR) T cells are genetically engineered autologous cells that express an activating receptor targeted towards one or more tumoral antigens. After ex vivo production and re-infusion, they are able to proliferate in the host and to recognize and kill tumor cells. Together with checkpoint inhibition, this new therapy is already being celebrated as a major medical breakthrough in recent years, due to the substantial benefit observed in clinical trials with patients with chemotherapy-refractory B‑cell malignancies...
2018: Memo
https://www.readbyqxmd.com/read/29983826/systemic-treatment-of-advanced-non-small-cell-lung-cancer-controversies-and-perspectives
#15
REVIEW
Andreas Tiefenbacher, Robert Pirker
Patients with advanced non-small cell lung cancer receive first-line therapy with chemotherapy, targeted therapies in case of tumors with driver mutations, and more recently also immune checkpoint inhibitors. Important controversies include the role of targeted therapies in combination with chemotherapy, optimal sequencing of treatments, treatment guidance by means of predictive biomarkers, and value-based judgements of treatments.
2018: Memo
https://www.readbyqxmd.com/read/29983825/chronic-lymphocytic-leukemia-at-ash-2017
#16
REVIEW
David Wanner, Michael Steurer
At ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together with a manageable safety profile in relapsed/refractory setting as well as in first line therapy of high-risk disease. These two combinations are potential new standard treatment options in chronic lymphocytic leukemia.
2018: Memo
https://www.readbyqxmd.com/read/29606982/esmo-2017-my-personal-highlights
#17
Barbara Kiesewetter, Mircea Dediu, Rupert Bartsch
This article is not intended to be a comprehensive review of all highlights presented at the recent ESMO Annual Meeting, but rather a summary from a personal point of view in three very different fields of oncology. Breast cancer and lung cancer are traditionally in the focus of interest, and again, relevant new data were presented. The third part of this overview is focused on novel treatment strategies in malignant lymphoma, a field that is also quickly evolving and traditionally underrepresented at meetings dealing with solid cancers...
2018: Memo
https://www.readbyqxmd.com/read/29606981/pleural-effusion-in-11-14-translocation-q1-multiple-myeloma-in-the-setting-of-proteasome-inhibitor-presents-therapeutic-complexity
#18
Malik Ghannam, Maria Bryan, Erik Kuross, Brent Berry
Background: Primary malignant pleural effusion has been reported in about 134 cases of multiple myeloma (MM). Associated pleural effusions in cases of MM portend a poor prognosis and identifying them is highly relevant. Reported is the case of a man diagnosed with MM who developed primary myelomatous pleural effusion in the setting of multiple relapses and subsequent mortality within 2 months of the pleural effusion diagnosis. Presentation: A 61-year-old African American man was diagnosed with MM in 2011...
2018: Memo
https://www.readbyqxmd.com/read/29606980/short-overview-on-the-current-standard-of-treatment-in-newly-diagnosed-multiple-myeloma
#19
REVIEW
Ella Willenbacher, Agnes Balog, Wolfgang Willenbacher
The treatment of newly diagnosed multiple myeloma has changed dramatically over the past 20 years, from near uniform application of chemotherapy to a patient performance status- and risk-based approach. Furthermore, initiation of treatment criteria have evolved from a pure end-organ damage-based definition to include risk factors of transformation to frank myeloma. Besides, the mainly cytogenetically defined Multiple Myeloma (MM) risk status, transplant eligibility of patients still serves primarily to allocate patients within a rational treatment algorithm...
2018: Memo
https://www.readbyqxmd.com/read/29606979/pd-1-and-pd-l1-inhibitors-after-platinum-based-chemotherapy-or-in-first-line-therapy-in-cisplatin-ineligible-patients-dramatic-improvement-of-prognosis-and-overall-survival-after-decades-of-hopelessness-in-patients-with-metastatic-urothelial-cancer
#20
REVIEW
Irene Resch, Shahrokh F Shariat, Kilian M Gust
Until recently, there were no true innovations in the management of locally advanced (aUC) and metastatic urothelial cancer (mUC) in the last three decades. Vinflunine has been approved by the EMA (European Medicines Agency) with only limited improvement compared to best supportive care in second line treatment. In addition, gemcitabine/cisplatin has been established as an alternative to methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). The advent of checkpoint inhibitors (CPI) revolutionized the care of these patients, transforming a unanimously deadly disease into one with hope through sustained disease control...
2018: Memo
journal
journal
41897
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"